N-[4-[4-(diethylaminomethyl)triazol-1-yl]phenyl]-3-methoxyaniline | 1173002-45-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[4-[4-(diethylaminomethyl)triazol-1-yl]phenyl]-3-methoxyaniline
• CAS: 1173002-45-3
• 化学式: C₂₀H₂₅N₅O
• 分子量: 351.451
• InChiKey: QQRKFAQBBZDZQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES
  申请人：Tazi Jamal

  公开号：US20110053975A1

  公开（公告）日：2011-03-03

  The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

  本发明涉及公式I至XXI中的化合物之一；包含至少一种这种化合物的药物组合物；以及使用至少一种这种化合物来制备一种药物，用于治疗主体中由至少一个剪接异常导致的遗传疾病。
• COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY
  申请人：Scherrer Didier

  公开号：US20140206690A1

  公开（公告）日：2014-07-24

  The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C 1 -C 4 )alkoxy group, a fluoro(C 1 -C 4 )alkoxy group, a hydroxyl group, a benzyloxy group, a di(C 1 -C 4 )alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C 1 -C 4 )alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO 2 NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH 2 ) n NR7R8 group or a hydroxy(C 1 -C 4 )alkyl group; R6 represents a hydrogen atom, a —(CHR9) m (CH 2 ) n NR7R8 group or a (C 1- C 6 )alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.

  本发明涉及化合物(I)，其中R1和R2分别表示氢原子，(C1-C4)烷氧基，氟(C1-C4)烷氧基，羟基，苄氧基，二(C1-C4)烷基氨基，吡啶基乙烯基，嘧啶基乙烯基，苯乙烯基或—NHCO苯基；R3，R4和R5分别表示氢原子，(C1-C4)烷基，CONHR6基，—CONR7R8基，—SO2NHR6基或杂环基，所述杂环基可选地被卤原子，—(CH2)nNR7R8基或羟基(C1-C4)烷基取代；R6表示氢原子，—(CHR9)m( )nNR7R8基或(C1-C6)烷基，可选地被羟基取代；或其药学上可接受的盐之一，用于预防，抑制或治疗患有p53失调的患者的疾病的方法。其中一些化合物是新的，也是本发明的一部分。
• CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS

  公开号：EP3536691A1

  公开（公告）日：2019-09-11

  The present invention relates to specific compounds; pharmaceutical composition comprising at least one of said compounds; and the use of at least one of said compounds in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

  本发明涉及特定化合物；包含至少一种所述化合物的药物组合物；以及使用至少一种所述化合物制备药物，以治疗受试者因至少一种剪接异常导致的遗传疾病。
• Compounds for use as therapeutic agents affecting P53 expression and/or activity
  申请人：ABIVAX

  公开号：US10538485B2

  公开（公告）日：2020-01-21

  The present disclosure relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.

  本公开涉及化合物 (I) 其中 R1 和 R2 独立地代表氢原子、(C1-C4)烷氧基、氟(C1-C4)烷氧基、羟基、苄氧基、二(C1-C4)烷基氨基、吡啶基乙烯基、嘧啶基乙烯基、苯乙烯基或 -NHCOphenyl 基；R3、R4 和 R5 各自代表氢原子、(C1-C4)烷基、CONHR6 基团、-CONR7R8 基团、-SO2NHR6 基团或任选被卤素原子、-(CH2)nNR7R8 基团或羟基(C1-C4)烷基取代的杂芳基；R6代表氢原子、-(CHR9)m( )nNR7R8基团或任选被羟基取代的(C1-C6)烷基；或其任何药学上可接受的盐，用于预防、抑制或治疗患者的疾病，所述疾病涉及p53失调。其中一些化合物是新化合物，也是本公开的一部分。
• Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US10654813B2

  公开（公告）日：2020-05-19

  Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.

  可用于治疗疾病（如杜氏肌肉萎缩症、艾滋病和早衰症）的化合物及其药学上可接受的盐类。这些化合物及其药学上可接受的盐可以是包括药学上可接受的支持物的药物组合物的一部分。